Navigation Links
Kill the cancer, not the patient: New toxicity testing approach could make chemo drugs safer
Date:11/18/2009

For cancer patients on chemotherapy, the "cure" can be as deadly as the disease itself. Adverse drug reactions are one of the leading causes of death among patients receiving cancer treatment.

Jackson Laboratory Professor Gary Churchill wants to change that. With a new two-year, $1 million grant from the National Cancer Institute, Churchill is launching a radical new approach to testing three chemotherapeutic drugs for potential toxic effects.

Chemo drugs are supposed to be toxicto cancer cells. But they're notorious for their unpredictable effectiveness and for causing systemic toxic reactions in patients.

"Adverse drug reactions can be difficult to study in humans," Churchill says. "Every individual is genetically unique and lives in an uncontrolled environment. That's why we need animal model systems to fully understand the genetic basis of drug response."

Testing chemo drugs in animal models is not new, but Churchill's approach is. Instead of working with one hybrid strain of mouse, as is the pharmaceutical industry standard, The Jackson Laboratory is developing a new mouse variety that is designed to maximize genetic diversity. Each one of these "Diversity Outbred Mice" will be genetically unique and, as a whole, the population approximates the genetic diversity observed in human populations.

To develop the Diversity Outbred Mice, Churchill is teaming up with Neal Goodwin, Ph.D., who directs cancer studies at JAXWest, The Jackson Laboratory's facility in Sacramento, Calif.

Sophisticated genetic mapping and live-animal imaging techniques will enable Churchill and Goodwin to home in on the gene variations found in mice that exhibit a toxic reaction. "So in terms of the information we're getting, it's almost like testing chemo drugs on every person on Earth," Churchill says. "This sets the scene for future, highly reliable screens for cancer patients."

The three drugs in the studydoxorubicin, cyclophosphamide, docetaxelwere chosen because of their well-known myelotoxic effects. Myelotoxicity or bone marrow suppression reduces the production of blood cells, hampering the body's ability to fight infection and causing anemia and other severe problems.

"We have chosen myelosuppression as the physiological response for this study," Churchill says, "because this adverse effect is a major contributor to morbidity, mortality and costs associated with cancer treatment. Mice are known to respond to these agents in a manner similar to humans, and the response can be measured using standard clinical hematological methods."

Imogen Hurley, Ph.D., an associate research scientist in Churchill's laboratory, notes that the approach behind these experiments will be relevant to all types of drugs. "Cancer drugs are an important test case. We expect to show that researchers will be able to use the genetic diversity of these mice to understand why individuals have different reactions to a wide range of drugs."


'/>"/>

Contact: Joyce Peterson
joyce.peterson@jax.org
207-288-6058
Jackson Laboratory
Source:Eurekalert

Related biology news :

1. Avocados may help prevent oral cancer, OSU study shows
2. St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory
3. Chemical in red wine, fruits and vegetables stops cancer, heart disease, depending on the dose
4. Exposure to low levels of radon appears to reduce the risk of lung cancer, new study finds
5. T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role
6. Fruits, vegetables and teas may protect smokers from lung cancer, UCLA researchers report
7. Control switches found for immune cells that fight cancer, viral infection
8. Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds
9. Landmark study opens door to new cancer, aging treatments
10. In lung cancer, silencing one crucial gene disrupts normal functioning of genome
11. UT Southwestern researchers disrupt biochemical system involved in cancer, degenerative disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., a ... simplifies the use and access of ubiquitous on-premise ... partnership with American Cyber.  ... experience leading transformational C4ISR and Cyber initiatives in ... the latest proven technology solutions," said Steve ...
(Date:1/11/2016)... Jan. 11, 2016 Synaptics Incorporated (NASDAQ: ... today announced that its ClearPad ® TouchView ™ ... won two separate categories in the 8 th ... Best Technology Breakthrough. The Synaptics ® TDDI solution ... supply chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... 4, 2016 - New FDA action date of ... New FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast ... decade indicated for the treatment of signs and symptoms of dry ... the potential to be the only product approved in the U.S. in the past decade ...
(Date:2/4/2016)... , Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... commercializing its flagship CytoSorb® blood filter to treat ... around the world, announced that CEO Dr. ... the Source Capital Group,s 2016 Disruptive Growth & ... the company.  Conference Presentation Details: ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... China , today announced that the ... February 4, 2016 a preliminary non-binding proposal letter, dated ... V-Ming ( Shanghai ) Investment Holdings Co., ... Shenzhen ) Fund Management Co., Ltd., Beijing ...
(Date:2/3/2016)... , Feb. 3, 2016  Discovery Laboratories, Inc. ... on developing aerosolized KL4 surfactant therapies for respiratory ... has approved an inducement award as a component ... its newly appointed President and Chief Executive Officer.  ... Committee on February 1, 2016 and granted as ...
Breaking Biology Technology: